To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

NCT05400876 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Lymphoma

Interventions

DRUG: TQB2618 injection
DRUG: Penpulimab injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.